Brokerages Set Diplomat Pharmacy Inc. (DPLO) PT at $17.80
Shares of Diplomat Pharmacy Inc. (NYSE:DPLO) have been given an average rating of “Hold” by the fourteen research firms that are covering the company. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $17.80.
A number of research analysts recently issued reports on the company. Zacks Investment Research downgraded Diplomat Pharmacy from a “buy” rating to a “hold” rating in a research note on Thursday, August 11th. Avondale Partners downgraded Diplomat Pharmacy from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 3rd. Leerink Swann downgraded Diplomat Pharmacy from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $35.00 to $18.00 in a research note on Thursday, November 3rd. TheStreet downgraded Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research note on Thursday, November 3rd. Finally, Credit Suisse Group AG reiterated a “hold” rating and issued a $18.00 target price on shares of Diplomat Pharmacy in a research note on Thursday, November 3rd.
COPYRIGHT VIOLATION NOTICE: This news story was published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally stolen and republished in violation of international copyright laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2016/12/01/brokerages-set-diplomat-pharmacy-inc-dplo-pt-at-17-80.html.
Shares of Diplomat Pharmacy (NYSE:DPLO) opened at 14.16 on Monday. The stock has a market capitalization of $941.80 million, a PE ratio of 29.20 and a beta of 1.21. The company’s 50 day moving average price is $20.32 and its 200 day moving average price is $29.80. Diplomat Pharmacy has a 12 month low of $12.47 and a 12 month high of $38.94.
Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings results on Wednesday, November 2nd. The company reported $0.21 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.24 by $0.03. The firm had revenue of $1.18 billion for the quarter, compared to analysts’ expectations of $1.26 billion. Diplomat Pharmacy had a return on equity of 10.47% and a net margin of 0.77%. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.26 EPS. Equities analysts anticipate that Diplomat Pharmacy will post $0.84 earnings per share for the current fiscal year.
In related news, EVP Atheer A. Kaddis sold 20,000 shares of Diplomat Pharmacy stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $30.12, for a total transaction of $602,400.00. Following the completion of the transaction, the executive vice president now directly owns 20,000 shares of the company’s stock, valued at $602,400. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 35.40% of the company’s stock.
A number of institutional investors have recently modified their holdings of the company. Advisor Group Inc. boosted its position in shares of Diplomat Pharmacy by 21.1% in the third quarter. Advisor Group Inc. now owns 3,614 shares of the company’s stock valued at $102,000 after buying an additional 629 shares in the last quarter. Sei Investments Co. purchased a new position in shares of Diplomat Pharmacy during the third quarter valued at about $139,000. BKS Advisors LLC purchased a new position in shares of Diplomat Pharmacy during the third quarter valued at about $140,000. Tower Research Capital LLC TRC boosted its position in shares of Diplomat Pharmacy by 12,630.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,201 shares of the company’s stock valued at $147,000 after buying an additional 4,168 shares in the last quarter. Finally, PineBridge Investments L.P. purchased a new position in shares of Diplomat Pharmacy during the second quarter valued at about $161,000. 77.02% of the stock is owned by hedge funds and other institutional investors.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions.
Receive News & Stock Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related stocks with our FREE daily email newsletter.